Evaluating dose of cisplatin responsible for causing nephrotoxicity.
Where this comes from
- Record sourced from PubMed, PMID 31022233.
- Also identified by DOI 10.1371/journal.pone.0215757 and PMC identifier 6483206.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nephrotoxicity is a well-known side effect of cisplatin for cancer treatment. Various regimens have been developed to treat cancer based on the type and severity of the tumor. We focus on the docetaxel, cisplatin, and 5-fluorouracil regimen, which is called the TPF regimen, where the standard dose of cisplatin is 60 mg/m2. The aim of this study is to examine the relationship of the dosage of cisplatin that causes nephrotoxicity and back ground factors of patients using information about the dose of cisplatin actually administered to patients. It is shown that nephrotoxicity may be caused by a substantially smaller dosage than the standard dose of cisplatin in the TPF regimen, indicating the need for dose adjustment, taking into account the patient's background factors in the treatment of a cancer.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Cisplatin
- Neoplasms
- Renal Insufficiency